DCF Valuation
Global Bio-chem Technology Group Company Limited (GBCMY) DCF Valuation — Is GBCMY undervalued?
The estimated DCF fair value of one Global Bio-chem Technology Group Company Limited (GBCMY) share is $18.25. Compared to the current market price of $4.14, the stock is undervalued by 341.3%.
DCF fair value
$18.25
Market price
$4.14
Upside / downside
+341.3%
Prefer the inverse question? See what growth rate the market is pricing into GBCMY →
Global Bio-chem Technology Group Company Limited (GBCMY) DCF valuation FAQ
What is the DCF fair value of Global Bio-chem Technology Group Company Limited (GBCMY)?
The discounted-cash-flow model estimates the intrinsic fair value of one Global Bio-chem Technology Group Company Limited (GBCMY) share at $18.25, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Global Bio-chem Technology Group Company Limited (GBCMY) overvalued or undervalued?
Against the current market price of $4.14, the DCF fair value of $18.25 implies GBCMY is undervalued by 341.3%.
How is the GBCMY DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Global Bio-chem Technology Group Company Limited's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Global Bio-chem Technology Group Company Limited files a new quarterly or annual report.
How this GBCMY valuation is built
The model projects ten years of Global Bio-chem Technology Group Company Limited's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Global Bio-chem Technology Group Company Limited's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Global Bio-chem Technology Group Company Limited files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-03.